Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$428560.0.

  • Regenerative Medical Technology's Net Cash Flow fell 29539.15% to -$428560.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$640151.0, marking a year-over-year decrease of 10816.97%. This contributed to the annual value of $635280.0 for FY2024, which is 15699.39% up from last year.
  • Regenerative Medical Technology's Net Cash Flow amounted to -$428560.0 in Q3 2025, which was down 29539.15% from -$598093.0 recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Net Cash Flow ranged from a high of $10.0 million in Q2 2021 and a low of -$7.8 million during Q4 2021
  • For the 5-year period, Regenerative Medical Technology's Net Cash Flow averaged around $24350.9, with its median value being -$81249.0 (2023).
  • Examining YoY changes over the last 5 years, Regenerative Medical Technology's Net Cash Flow showed a top increase of 1970364.62% in 2021 and a maximum decrease of 4565457.23% in 2021.
  • Quarter analysis of 5 years shows Regenerative Medical Technology's Net Cash Flow stood at -$7.8 million in 2021, then surged by 97.5% to -$193914.0 in 2022, then plummeted by 216.33% to -$613401.0 in 2023, then surged by 153.7% to $329393.0 in 2024, then tumbled by 230.11% to -$428560.0 in 2025.
  • Its Net Cash Flow was -$428560.0 in Q3 2025, compared to -$598093.0 in Q2 2025 and $57109.0 in Q1 2025.